Abstract:The domain of psychiatric drug development is currently witnessing a notable transformation, with a paramount emphasis on targeting nonmonoamine receptors and exploring inventive mechanisms of action. This paper presents an overview of the ongoing advancements in antipsychotic and antidepressant drug development. Historically, antipsychotics predominantly targeted dopamine receptors, but there is now an escalating interest in drugs that act on alternative receptors, exemplified by the TAAR1 receptor. One noteworthy candidate is Ulotaront (SEP-363856), an agent acting as a TAAR1 agonist with 5-HT1A agonist activity, demonstrating promising outcomes in the treatment of schizophrenia, devoid of extrapyramidal symptoms or metabolic side-effects. Similarly, MIN-101 (Roluperidone) and KarXT are currently in development, with its focus on addressing the symptoms in schizophrenia. In the domain of antidepressants, novel therapeutic approaches have surfaced, such as Auvelity, a Food and Drug Administration (FDA)-approved NMDA receptor antagonist synergistically combined with Bupropion to enhance its effects. Another notable candidate is Zuranolone, operating as a GABA A receptor-positive allosteric modulator, showcasing efficacy in treating major depressive disorder (MDD) and postpartum depression. Additionally, TAK-653 (NBI-1065845) and MJI821 (Onfasprodil) have emerged as potential antidepressants targeting AMPA receptors and NMDA receptor 2B (NR2B) negative allosteric modulation, respectively. This paper underscores the transformative potential of these novel drug candidates in psychiatric treatment and their ability to address cases that were previously treatment-resistant. By focusing on nonmonoamine receptors and introducing innovative mechanisms, these drugs offer a promising prospect of improved outcomes for individuals suffering from schizophrenia and MDD. Thus, sustained attention and dedication to the development of such drugs are essential to augmenting the therapeutic options available for psychiatric patients.

Innovative solutions to novel drug development in mental health.

Physiologically informed neuromodulation

Time to Re-Engage Psychiatric Drug Discovery by Strengthening Confidence in Preclinical Psychopharmacology

Neuropsychiatric drug development: Perspectives on the current landscape, opportunities and potential future directions

New directions in psychiatric drug development: promising therapeutics in the pipeline

Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

A plan for mental illness

Clinical pharmacological innovation in the treatment of depression

Impact in psychiatry research through experimentation, translation to industry, policy development and public engagement

Stratified Medicine for Mental Disorders.

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Drug targeting in psychiatric disorders - how to overcome the loss in translation?

Immunological Drivers and Potential Novel Drug Targets for Major Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

Translational Neuroscience: Toward New Therapies

Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms

Drug targets for cognitive enhancement in neuropsychiatric disorders

Novel treatments for anxiety and depression: hurdles in bringing them to the market

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy